OZ.VGI.CO.ID - Eli Lilly is strategically advancing its immunology pipeline with a focus on expanding the reach of its IL-23p19 inhibitor, Omvoh, into the pediatric segment for ulcerative colitis (UC). This move aims to secure a more prominent position for the drug in the highly competitive inflammatory bowel disease (IBD) market.
Promising Phase 3 Results in Young Patients
The Indianapolis-based pharmaceutical giant recently announced positive outcomes from its pivotal Shine-2 Phase 3 trial.
This study evaluated Omvoh's efficacy and safety in pediatric patients, aged six to 17 years, who were experiencing moderately to severely active ulcerative colitis.
The trial met its primary endpoint, with half of the children who responded to the initial induction therapy achieving clinical remission by the one-year mark.
Lilly has highlighted this as a significant milestone, noting it as the first Phase 3 study of an IL-23p19 inhibitor to report one-year results in a pediatric population.
Omvoh: A Dual-Action Approach to IBD Treatment
Omvoh, recognized as a first-in-class biologic, employs a distinct treatment regimen.
It begins with a 12-week intravenous (IV) induction phase, followed by monthly subcutaneous injections for maintenance.
This biologic already holds approvals for treating adult IBD, having received its initial UC approval in 2023 and subsequently gaining approval for Crohn's disease in 2025.
The company's strategy now hinges on leveraging these established adult credentials to penetrate the pediatric market.
Regulatory Pathway and Global Aspirations
Following the positive Shine-2 trial results, Eli Lilly has declared its intention to submit the comprehensive data to regulatory bodies, including the U.S.
Food and Drug Administration (FDA) and other global health authorities.
This submission is a critical step toward obtaining a pediatric label expansion for Omvoh.
The data was simultaneously presented at the United European Gastroenterology Week in Barcelona, underscoring the global significance of these findings.
Addressing the Pediatric IBD Burden
Mark Genovese, M.D., senior vice president of Lilly's immunology development, emphasized the critical need for effective treatments in pediatric UC.
"UC affects more than 25,000 U.S. kids, and the pediatric presentation is often aggressive and severe in nature, more so than the initial adult presentation," Dr.
Genovese stated.
He described the observed 50% remission rate in the Shine-2 trial as "absolutely phenomenal" and indicative of delivering "really high benefit" to this vulnerable patient group.
Trial Demographics and Efficacy Details
The Shine-2 trial specifically enrolled pediatric patients with active UC, ensuring that the study population reflected individuals with a clear need for treatment.
A total of 63 participants were enrolled.
Notably, more than half of these children had previously undergone treatment with another biologic or advanced therapy, yet continued to experience active disease, highlighting the challenging nature of their conditions.
Within the enrolled patient cohort, an impressive 81% demonstrated a response to Omvoh's induction therapy within the initial 12 weeks.
Of this group of responders, a substantial 73% maintained their clinical response one year into the treatment.
Delving deeper into the remission metrics, half of all patients achieved clinical remission after one year.
Further analysis revealed that 50% also attained corticosteroid-free remission, meaning they had not used corticosteroids in the preceding 12 weeks.
Additionally, 44% achieved endoscopic remission, indicating no visible signs of disease in their digestive tract after a year of Omvoh treatment.
Dr.
Genovese stressed that the trial did not focus on mild cases.
"Fifty percent of these children met the modified Mayo score for severe disease, meaning a score of seven to nine," he informed Fierce, underscoring the severity of the UC experienced by the study participants.
Safety Profile and Market Context
The safety profile observed in the pediatric trial was consistent with the data previously gathered from Omvoh's adult UC studies.
The most frequently reported adverse event among the young participants was upper respiratory infection.
This consistency in safety is a positive indicator as the drug seeks broader regulatory approval.
Despite Omvoh's established presence and positive long-term data in the adult UC market, Eli Lilly faces significant competition.
Established biologics such as Skyrizi, Tremfya, and Stelara currently hold substantial market share.
In the second quarter of its most recent earnings report, Omvoh generated $102 million in sales, representing a 36% increase from the $75 million earned in the same period in 2025.
However, AbbVie's Skyrizi, approved for UC in 2024, reportedly captures approximately three-quarters of first-line IL-23 prescriptions for IBD.
The Pediatric IBD Frontier: A Less Crowded Arena
The pediatric IBD market, while smaller, presents a less saturated competitive environment.
Currently, no other IL-23p19 inhibitors are approved for use in this age group.
Johnson & Johnson's Stelara, a dual IL-12/23 inhibitor, made significant inroads earlier this year by securing FDA approvals for pediatric Crohn's disease and UC in children as young as two years old.
This marked a notable achievement as it was the first non-TNF drug to gain such pediatric indications.
Should Omvoh receive approval for pediatric UC, Stelara and its upcoming biosimil versions would become direct competitors.
While direct comparisons between separate clinical trials are complex, preliminary observations suggest a nuanced competitive landscape.
Stelara's Phase 3 study reported a 52-week clinical remission rate and steroid-free remission rate of 40%, which are lower than Omvoh's reported figures.
However, Stelara demonstrated a higher symptomatic remission rate at 65%.
It is also worth noting that Stelara's Phase 3 trial involved twice the number of patients compared to Omvoh's Shine-2 study.
Lilly's Strategic Positioning and Future Outlook
In the adult market, Eli Lilly has strategically positioned Omvoh as a valuable option for patients who have not responded adequately to other biologic therapies.
Post-hoc analyses from the company's adult IBD programs have indicated that Omvoh can achieve multiple treatment objectives simultaneously in both UC and Crohn's disease over a year, benefiting both patients new to biologics and those with prior biologic failure.
Dr.
Genovese further elaborated on the unmet needs in pediatric IBD: "After ustekinumab, there aren’t many therapies available for pediatrics," he commented, referring to Stelara by its generic name.
"We’re enthusiastic about the idea we’re doing something for kids." This sentiment underscores Lilly's commitment to addressing the specific challenges faced by young patients with IBD.
The pursuit of a pediatric label expansion for Omvoh signifies Eli Lilly's intent to broaden the therapeutic options available for children suffering from ulcerative colitis, potentially offering a new avenue for managing this chronic condition in a younger demographic.
Note: Decisions regarding treatment for ulcerative colitis, especially in pediatric populations, are complex and should always be made in consultation with qualified healthcare professionals. This article provides information based on published clinical trial data and company announcements, and does not constitute medical advice.

Comments